My research focuses on the chemopreventive potential of pharmacological agents in urothelial carcinogenesis. I am particularly interested in exploring how drugs originally developed for non-oncologic diseases—such as pioglitazone, an antidiabetic agent—can modulate key molecular pathways involved in malignant transformation. Using a chemical carcinogen-induced in vitro model, my work investigates the effects of pioglitazone on cell proliferation, migration, and gene/protein expression in human urothelial cells. This research has broader implications for drug repurposing and cancer prevention. My academic interests also extend to molecular oncology, and the integration of laboratory findings into clinical applications.
My research focuses on the chemopreventive potential of pharmacological agents in urothelial carcinogenesis. I am particularly interested in exploring how drugs originally developed for non-oncologic diseases—such as pioglitazone, an antidiabetic agent—can modulate key molecular pathways involved in malignant transformation. Using a chemical carcinogen-induced in vitro model, my work investigates the effects of pioglitazone on cell proliferation, migration, and gene/protein expression in human urothelial cells. This research has broader implications for drug repurposing and cancer prevention. My academic interests also extend to molecular oncology, and the integration of laboratory findings into clinical applications.